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1. Introduction
Cystic fibrosis (CF) is the most frequent lethal auto-
somal recessive disease among Caucasians. In more than
90% of all patients the pulmonary involvement is the
life-limiting factor. In the lung, the production of viscous
sputum is a main and early clinical feature of CF. To
help clear the lungs from this material mucolytic active
drugs were used. Recombinant human DNase (rhDNase)
w1x and hypertonic (5.85%) saline (HS) w2x both were
mucolytic active and improved FEV1 in the same range
in patients with CF. Besides this similarity there are dif-
ferences such as the modulation of rheological parame-
ters and costs. To determine whether these treatments
can replace each other, we compared effect and accep-
tance in the same group of patients.
2. Methods
Fourteen patients (8 male and 6 female), age
mean(S.D.) 13.3(2.9) years with cystic fibrosis (CF)
and mild to moderate pulmonary involvement
mean(S.D.) FEV1(%predicted) 75.6%(14%) were
investigated in a randomised cross-over pilot study. Nine
patients were chronically Pseudomonas aeruginosa
(PSA) colonised, 3 patients were free of PSA and in 2
patients PSA were intermittently detectable in sputum
cultures with no PSA-antibody in serum. All chronically
PSA colonised patients were on daily inhalation of anti-
biotics (tobramycin 2=80 mg or colistin 2=10 units6
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per day). Exclusion criteria were the use of rhDNase or
hypertonic saline (HS) in the past, respiratory infection
requiring intravenous antibiotics within the previous 3
weeks, allergic bronchopulmonary aspergillosis (ABPA)
and colonisation with Burkholderia cepacia. The
patients’ routine medication was not altered during the
study. There were two treatment periods of 3 weeks
duration with a 3-week washout. Treatment consisted of
2 puffs salbutamol via a spacer prior to inhalation of 10
ml HS b.i.d. or 2.5 mg (2 ml) rhDNase once daily. The
same nebulizer (Pari Master with Pari LL) with an
interrupter was used for HS and rhDNase. The interven-
tion was not blinded because the taste of HS and the
different volume made it impossible. Patients were ran-
domised in groups of four and drew lots to start with
either HS or rhDNAse. All patients were on salbutamol
regularly. Patients were assessed before and after each
period. Additional pulmonary function tests were per-
formed before and after the first inhalation of HS. At the
end of each treatment period patients were asked to give
a score to their general acceptance of the new treatment.
The score was related to school marks from 1 to 6 (1s
very good, 2sgood, 3ssatisfying, 4ssufficient, 5s
inadequate and 6sunacceptable). At the end of each 3-
week treatment period the patients reported how much
time they needed for inhalation. Changes from baseline
for FEV1(%predicted) were compared using the non-
parametric Wilcoxon rank sum test for cross-over design
w3x. Acceptance scores were compared using non-para-
metric Wilcoxon rank sum test. FEV1 changes and mean
inhalation time were correlated to acceptance score with
Pearson correlation tests.
The study was approved by the ethical committee of
the Medical School Hannover. Patientsyparents gave
written informed consent.
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Fig. 1. Changes of FEV1(% predicted) from baseline are shown after 3 weeks treatment with HS (j) and with rhDNase (h) for each single
patient. Patient no. 8 showed no change with HS.
3. Results
3.1. Pulmonary function
FEV1(mean(S.D.)) increased 7.7%(14%) with HS
(P-0.05) and 9.3%(11.7%) with rhDNase (P-0.05)
over baseline with no phase or carryover effect. These
increases were not significantly different between rh-
DNase and HS. Fig. 1 showed the individual changes of
FEV1 and the intra-individual variation of the responses.
The increase of FEV1(% predicted) was clinically rel-
evant ()10% from baseline) in 4 patients with HS
alone, 4 patients with rhDNase alone and in 2 patients
with both treatments (see Fig. 1).
To avoid acute bronchospasm, two puffs of salbutamol
were inhaled prior to inhalation of HS. With this pre-
treatment we, like others w2,6x, could not demonstrate an
acute clinically significant decline in FEV1 with the
inhalation of HS.
The acceptance of the treatment was scored by the
patients at the end of each treatment period with median
(range) 2 (1–3) for rhDNase and 5 (2–6) for HS (P-
0.005).
3.2. Inhalation time
The inhalation time (mean(S.D.)) was shorter with
rhDNase 11(6) min vs. twice 42(11) min with HS (P-
0.05).
3.3. Correlations
There was no significant correlation between accep-
tance score and changes in FEV1(% predicted) but there
was correlation between acceptance score and duration
of inhalation (rs0.73, P-0.01).
4. Discussion
In this short-term pilot study we demonstrated the first
evidence that the effects of HS and rhDNase on FEV1(%
predicted) were comparable in a group of mild to mod-
erately severe ill children with CF. As expected w4x,
approximately 30% of patients showed a clinically rel-
evant increase of FEV1 ()10%) with rhDNase and the
same was observed for HS. The substantial variations in
the same individual in the response to HS or rhDNase
might reflect the diverse influences of HS (viscoelastic-
ity) and rhDNase (spinnability) on sputum which might
have different relevance in the individual patient w5x.
Should a patient not respond to HS he might be suc-
cessfully treated with rhDNase and vice versa.
A recent report raised the question of whether an
increased concentration of sodium and chloride in the
airway surface liquid (ASL) is harmful w7x or not. A
high concentration of NaCl in ASL was described in
patients with CF and related to its failure of killing bac-
teria. Other earlier w8x reports support the observation of
high concentrations of NaCl while more recent studies
reported no difference between CF and healthy control
subjects w9–11x. If the concentrations of NaCl in ASL
were compared in non-CF, CF with infection (on the
basis of bronchoalveolar lavage) and CF without infec-
tion in a group of infants, only infants with CF and infec-
tion had abnormally low chloride concentrations w10x. A
very recent study reported a salt-independent abnormal-
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ity of antimicrobial activity in CF airway surface fluid
w12x. In summary, there seems to be enough evidence
that HS in patients with CF is not harmful. However, as
indicated by the scores, rhDNase was much better
accepted than HS. This might be mainly related to the
much shorter inhalation time of rhDNase compared to
HS as demonstrated by the correlation between accep-
tance and inhalation time. In this pilot study we decided
to use the same nebulizer for rhDNase and HS to make
the results independent of the type of nebulizer and
therefore more comparable. The price of rhDNase makes
it difficult for healthcare systems to provide this drug to
everyone who might profit from its use. HS is inexpen-
sive, simple to store and has, therefore, a chance of being
available to many patients everywhere. Nevertheless, the
optimal application (volume and nebulizer) and ideal
concentration w6x of HS which improve pulmonary func-
tion and is still acceptable in daily life have to be
determined.
In conclusion we demonstrated first evidence for a
comparable increase in FEV1 with rhDNase and HS but
these results have to be confirmed in a larger study.
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